This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Osanai, T. Articles by Okumura, K. Search for Related Content PubMed PubMed Citation Articles by Osanai, T. Articles by Okumura, K. Related Collections Related Article

(Circulation Research. 2007;100:1106.)
© 2007 American Heart Association, Inc.

Editorials

Therapeutic Challenge to Adiposity of the Heart

Tomohiro Osanai, Ken Okumura

From the Second Department of Internal Medicine (T.O., K.O.), Hirosaki University School of Medicine, Hirosaki, Japan.

Correspondence to Ken Okumura, MD, the Second Department of Internal Medicine, Hirosaki University School of Medicine, 5 Zaifu-Cho, Hirosaki, 036-8562 Japan. E-mail okumura@cc.hirosaki-u.ac.jp

See related article, pages 1208–1217

Key Words: diabetes • obesity • fatty acid transporter • lipotoxic cardiomyopathy

An extract of the first 250 words of the full text is provided, because this article has no abstract.

The recent increase in the prevalence of obesity is one possible explanation for the adverse trends in cardiovascular morbidity and mortality. Hospitalizations for congestive heart failure have increased, and the decline in death because of coronary heart disease has leveled off. In parallel with these aspects, there is emerging evidence that inherited and acquired cardiomyopathies are associated with marked intracellular lipid accumulation in the heart.^1–5 Three types of mismatches between uptake and utilization of long chain fatty acid (LCFA) lead to abnormally high intracellular LCFA concentrations in the heart, resulting in lipotoxic cardiomyopathy. First, inborn errors in myocardial ß-oxidation are associated with heart failure, arrhythmias, sudden death, and pathologic lipid accumulation with a 3-fold increase in phospholipids and 100-fold increase in triglycerides in the myocardium.¹ Second, myocardial metabolism switches from utilization of LCFA to utilization of glucose during the development of cardiac hypertrophy and in the ischemic and failing heart. Although this metabolic switch initially serves an adaptive function, accumulation of intracellular LCFA in these acquired conditions contributes to contractile dysfunction and the generation of cardiac arrhythmias.² Third, several-fold increased cardiac myocyte triglyceride stores are observed in animal models of obesity and diabetes, in which high serum free fatty acid levels promote LCFA uptake in excess of tissue capacity for utilization.^3,4 This lipid accumulation contributes to cardiac myocyte apoptosis by nonoxidative metabolic pathways, such as ceramide synthesis, and to congestive heart failure (Figure). Even in humans, myocardial lipid content has been recently reported to increase with the degree . . . [Full Text of this Article]

Related Article:

CD36 Deficiency Rescues Lipotoxic Cardiomyopathy

John Yang, Nandakumar Sambandam, Xianlin Han, Richard W. Gross, Michael Courtois, Attila Kovacs, Maria Febbraio, Brian N. Finck, and Daniel P. Kelly
Circ. Res. 2007 100: 1208-1217. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

				M. C. Sugden PDC deletion: the way to a man's heart disease Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H917 - H919. [Full Text] [PDF]

				J. Smith, X. Su, R. El-Maghrabi, P. D. Stahl, and N. A. Abumrad Opposite Regulation of CD36 Ubiquitination by Fatty Acids and Insulin: EFFECTS ON FATTY ACID UPTAKE J. Biol. Chem., May 16, 2008; 283(20): 13578 - 13585. [Abstract] [Full Text] [PDF]